This website was developed to provide an accurate method to calculate a total AML-CM score that can be used
to predict mortality after initial therapy for patients with newly diagnosed AML. The AML-CM comprises of the
augmented HCT-CI to capture comorbidity burdens, patient’s age and cytogenetic/molecular risks per the
European Leukemia Network (ELN) classification  to capture AML resistance to therapy.
The AML-CM was designed and validated in a group of 1100 patients with newly diagnosed AML, who were treated between 2008-2012 at five academic institutions led by the Seattle Cancer Care Alliance (SCCA)/Fred Hutchinson Cancer Research Center (FHCRC), Massachusetts General Hospital, Cleveland Clinic, Stanford University, University of Utah.
Click below on the Calculator button to proceed to the AML-CM calculator.